...Levent Ozcan; Emre Can Polat; Caner Baran; Ahmet Boylu; Mustafa Erkoc; Alper Otunctemur Introduction: The main challenge to the optimal use of neoadjuvant chemotherapy (NAC) is the difficulty in selecting patients who may or may not benefit from NAC. Our aim in this study was to investigate whether...

... the adaption of neoadjuvant chemotherapy (NAC) in patients with muscle-invasive bladder cancer (MIBC) in Germany, Austria, and Switzerland and especially underlying reasons for potential low adherence to guidelines. Methods: We conducted a non-validated survey among 336 urologic departments in Germany, Austria...

... widely accepted than NAC. NAC and AC were generally administered by urologists. Adjuvant chemotherapy Bladder cancer Neoadjuvant chemotherapy Gemcitabine Cisplatin Survey Bladder cancer is the seventh most common cancer in the male population and the 11th most common when considering both...

..., adequate follow-up is needed to assess the ability of neoadjuvant chemotherapy to improve the prognosis of patients with locally advanced urothelial cancer of the upper urinary tract. 19 12 1994 23 01 1995 3 2 2010 Original Paper Urol Int 1995:55:74-77 M. Igawaa S . Urakamia H. Shiinaa...